Bryn Mawr Trust Advisors LLC Has $2.79 Million Stock Holdings in Amgen Inc. $AMGN

Bryn Mawr Trust Advisors LLC lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 13.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,988 shares of the medical research company’s stock after selling 1,619 shares during the quarter. Bryn Mawr Trust Advisors LLC’s holdings in Amgen were worth $2,789,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Paulson Wealth Management Inc. lifted its holdings in shares of Amgen by 86.9% during the second quarter. Paulson Wealth Management Inc. now owns 2,981 shares of the medical research company’s stock worth $832,000 after buying an additional 1,386 shares during the last quarter. Twin Capital Management Inc. grew its stake in shares of Amgen by 1.5% in the second quarter. Twin Capital Management Inc. now owns 20,321 shares of the medical research company’s stock worth $5,674,000 after acquiring an additional 304 shares during the last quarter. Soltis Investment Advisors LLC increased its position in Amgen by 3.9% during the second quarter. Soltis Investment Advisors LLC now owns 18,557 shares of the medical research company’s stock worth $5,181,000 after acquiring an additional 697 shares during the period. Cetera Trust Company N.A raised its stake in Amgen by 0.7% during the 2nd quarter. Cetera Trust Company N.A now owns 9,353 shares of the medical research company’s stock valued at $2,611,000 after purchasing an additional 65 shares during the last quarter. Finally, Achmea Investment Management B.V. increased its position in shares of Amgen by 34.1% during the second quarter. Achmea Investment Management B.V. now owns 201,714 shares of the medical research company’s stock valued at $56,320,000 after purchasing an additional 51,293 shares during the period. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AMGN shares. Wells Fargo & Company upped their target price on Amgen from $280.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday. Raymond James Financial initiated coverage on shares of Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. UBS Group decreased their target price on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Guggenheim upped their target price on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, Piper Sandler restated an “overweight” rating on shares of Amgen in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $308.83.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.76% of the company’s stock.

Amgen Stock Up 1.5%

Shares of NASDAQ AMGN opened at $320.20 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88. The firm’s 50-day simple moving average is $289.94 and its 200 day simple moving average is $288.50. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The company has a market cap of $172.38 billion, a price-to-earnings ratio of 26.18, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same period in the previous year, the firm posted $5.58 earnings per share. The company’s revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, November 21st. Amgen’s payout ratio is 73.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.